NHPC 2015: High Rates of HIV Found Among Trans Women
- Details
- Category: Transgender People
- Published on Tuesday, 16 February 2016 00:00
- Written by HIVandHepatitis.com
Although transgender people -- especially trans women of color -- have among the higher rates of HIV infection, this population has not been adequately studied. Many HIV prevention studies have miscategorized transgender women as men who have sex with men, and there has been little specific research on HIV among trans men.
Coverage of the 2015 National HIV Prevention Conference
- Details
- Category: HIV Prevention
- Published on Thursday, 17 December 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2015 National HIV Prevention Coference, (NHPC 2015), December 6-9 in Atlanta.
Conference highlights include HIV pre-exposure prophylaxis (PrEP), antiretroviral treatment as prevention, syringe exchange, and addressing disparities in HIV incidence and outcomes.
7/22/15
NHPC 2015: U.S. Syringe Funding Ban Impedes HIV and Hepatitis C Prevention
- Details
- Category: Injection Drug Use
- Published on Tuesday, 15 December 2015 00:00
- Written by Liz Highleyman
Providing sterile syringes is a proven effective method for preventing HIV and hepatitis C virus (HCV) infections among people who inject drugs, yet the U.S. government continues to prohibit use of federal funds for this purpose, presenters said at the 2015 National HIV Prevention Conference (NHPC) last week in Atlanta. A federal budget bill now under consideration could lift the funding ban on syringe exchange programs.
NHPC 2015: Evidence for PrEP Efficacy Grows, but Implementation Presents Challenges
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 16 December 2015 00:00
- Written by Liz Highleyman
Pre-exposure prophylaxis (PrEP) was a major topic at the 2015 National HIV Prevention Conference(NHPC) last week in Atlanta. A growing body of evidence continues to confirm that Truvada PrEP is highly effective for preventing HIV if taken regularly, both in clinical trials and in real-world clinical use. Yet uptake has been uneven, and researchers and front-line health workers are learning about barriers to PrEP implementation and scale-up for diverse population groups.
Web Design and Development by